AMICUS THERAPEUTICS INC (FOLD)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for FOLD
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| FOLD | Founder & President | 68 | ["Former senior executive of Amgen, Inc.", "More than two decades of executive experience in life sciences industry", "Former audit committee chairman for Direct Relief", "BSc in business administration from Florida A&M University"] | ["Audit Committee", "Audit and Compliance", "Nominating andCorporate Governance"] | 2025 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| HRI | Retired Executive Vice President of the Electronics and Energy Business; Director | 69 | ["Retired Executive Vice President of the Electronics and Energy Business of 3M Company", "Retired Executive Vice President, Electronics and Energy Business of 3M Company", "Former Executive Vice President of the Display and Graphic Business at 3M", "Experience in various management positions in the U.S., Singapore, Korea and Germany", "Knowledge and experience in strategic planning, restructuring and general operational matters", "Broad understanding of the responsibilities of public company boards"] | ["Compensation Committee", "Nominating and Governance Committee"] | 2026 |
| NEO | Director; Board Member and Chair of the Audit and Finance Committee | 68 | ["former senior executive of Amgen, Inc.","Founder & President of Sentry Hill Partners, LLC","more than two decades of executive experience in life sciences industry","served in various strategic finance and operations positions","Senior Vice President, Global Business Services at Amgen","Vice President & CFO, International Commercial Operations at Amgen","held positions at Biogen, Tanox, and Monsanto Life Sciences","currently serves as a director for Amicus Therapeutics, DMC Global, Inc., and Prime Medicine, Inc.","former audit committee chair for Direct Relief","holds a BS in business administration concentrating in Finance and Industrial Relations"] | ["Audit and Finance Committee","Compliance Committee"] | 2025 |
| BOOM | Director | ["Diversified background in finance, operations and the life sciences industry", "Extensive skills in executive leadership, finance, operations and management", "In-depth experience with a multinational company operating in global markets", "More than two decades of executive experience in senior leadership roles in the life sciences industry", "Founded and served as President of Sentry Hill Partners, LLC since January 2018", "Worked at Amgen, Inc. from 2003 to 2017, most recently as Senior Vice President, Global Business Services", "Served as Chief Financial Officer of Tanox, Inc. from 2000 to 2003", "Vice President, Finance and Corporate Controller of Biogen, Inc. from 1998 to 2000", "Vice President, Finance and Chief Financial Officer of Nutrasweet Kelco Company from 1996 to 1998", "Served on the board of directors of HOOKIPA Pharma, Inc. from February 2019 to April 2023", "Holds a bachelor\u2019s degree in Business Administration from Florida A&M University"] | ["Compensation (Chair)", "Corporate Governance and Nominating", "Risk"] | 2025 |
Biography sourced from the proxy statement filing.
Michael A. Kelly has served as a member of the Board since December 2020. Mr. Kelly is a former senior executive of Amgen, Inc. (Nasdaq: AMGN), a multinational biopharmaceutical company, and is currently acting as Founder & President of Sentry Hill Partners, LLC, a global life sciences transformation and management consulting business founded by Mr. Kelly in 2018. Mr. Kelly has more than two decades of executive experience as a senior leader in the life sciences industry serving in various strategic finance and operations positions at Amgen Inc., most recently as Senior Vice President, Global Business Services and Vice President & CFO, International Commercial Operations. Mr. Kelly has also held positions at Biogen, Inc. (Nasdaq: BIIB), Tanox, Inc., and Monsanto Life Sciences, a division of the Nutrasweet Kelco Company. Currently, Mr. Kelly is an independent member of the Board of Directors for each of Prime Medicine, Inc. (Nasdaq: PRME), DMC Global, Inc. (Nasdaq: BOOM), and NeoGenomics, Inc. (Nasdaq: NEO). Mr. Kelly previously served on the Boards of Directors for Aprea Therapeutics, Inc. (Nasdaq: APRE) and Hookipa Pharma, Inc. (Nasdaq: HOOK). He also serves on the Council of Advisors and was the former audit committee chairman for Direct Relief, a humanitarian aid organization focused on health outcomes and disaster relief. Mr. Kelly holds a BSc in business administration from Florida A&M University, concentrating in Finance and Industrial Relations. Skills and Qualifications : Mr. Kelly brings more than two decades of leadership experience in the life sciences industry and a wealth of knowledge and background in managing, financing, and growing global healthcare and biotechnology companies to the Board. He has served in various strategic finance and commercial operations positions, including, Founder and President of a global life sciences transformation and management consulting business, Chief Financial Officer, and Board member of multiple biotechnology companies. Mr. Kelly also has extensive experience in developing and executing global corporate strategies for multi-product biotechnology organizations, a special skill set in organizational development, as well as leadership experience in humanitarian aid facing organizations focused on health outcomes and disaster relief. Mr. Kelly s skills and experience and the substantial time he devotes to Amicus matters contributed to our conclusion that he should continue to serve as a director of the Company and as member of the Audit and Compliance and Science and Technology committees.